CAS9-nucleic acid complexes and uses related thereto

Patent metadata

Field	Value
Publication number	US-11312945-B2
Application number	US-201916507745-A
Country	US
Kind code	B2
Filing date	Jul 10, 2019
Priority date	Jan 16, 2013
Publication date	Apr 26, 2022
Grant date	Apr 26, 2022

Abstract

This disclosure relates to Cas9-nucleic acid complexes and uses related thereto. In certain embodiments, the disclosure contemplates transgenic plants and animals genetically engineered to express Cas9-nucleic acid complexes disclosed herein. In certain embodiments, the disclosure relates to methods of treating or preventing, diseases, conditions, cancer, viral infections or other pathogenic infection using vectors configured to express a Cas9-nucleic acid complex disclosed herein.

First claim

What we claim:

1. A recombinant nucleic acid comprising:
a sequence comprising a Cas9 gene,
a sequence encoding an RNA, wherein the RNA comprises a first segment that is configured to bind with the Cas9 after transcription and a second segment that is configured to bind a target nucleic acid,
wherein the target nucleic acid sequence is mRNA produced by the transcription of a PD1 (Programmed cell death 1) gene or PD-L1 (Programmed cell death ligand 1) gene.

2. The recombinant nucleic acid of claim 1 , wherein the Cas9 is a bacterial Cas9.

3. The recombinant nucleic acid of claim 2 , wherein the bacterial Cas9 encodes Cas9 having SEQ ID NO: 1 or conserved variants thereof.

4. The recombinant nucleic acid of claim 3 , wherein the bacterial Cas9 has an arginine-rich, RuvC-III, and RuvC-IV motif.

5. The recombinant nucleic acid of claim 4 , wherein the bacterial Cas9 encodes bacterial Cas9 with an arginine rich motif, RuvC-III motif, and RuvC-IV motif, wherein Cas9 has greater than 40% identity to SEQ ID NO: 1, wherein the arginine rich motif has greater than 40% identity to SEQ ID NO: 6, wherein the RuvC-III motif has greater than 40% identity to SEQ ID NO: 7, and wherein the RuvC-IV motif has greater than 40% identity to SEQ ID NO: 8.

6. The recombinant nucleic acid of claim 1 , wherein the first segment comprises a sequence with 60% or more identity to SEQ ID NO: 5 or SEQ ID NO: 11.

7. The recombinant nucleic acid of claim 1 , wherein the first segment forms a hairpin structure.

8. The recombinant nucleic acid of claim 1 , wherein the second segment of RNA is single stranded.

9. The recombinant nucleic acid of claim 1 , wherein the second segment comprises more than 10, 15, 20, 25, 30, 50, or 100 continuous nucleotides configured to hybridize to a target sequence.

10. The recombinant nucleic acid of claim 1 , wherein the Cas9 gene is a human, animal, or plant codon optimized sequence.

11. The recombinant nucleic acid of claim 10 , wherein the Cas9 gene comprises a sequence with 60% or more identity to SEQ ID NO: 9.

12. A recombinant vector comprising the recombinant nucleic acid of any one of claims 7 and 8 - 11 .

13. The recombinant vector of claim 12 selected from a genetically engineered plasmid, bacteriophage, bacterial artificial chromosome, yeast artificial chromosome, or a virus.

14. A bacterial, prokaryotic, eukaryotic, insect, mammalian, or plant cell transformed with the recombinant vector of claim 13 .

Assignees

• Univ Emory

Inventors

• Weiss David S
• Grakoui Arash
• Sampson Timothy R
• Price Aryn Alaine

Classifications

• A61K39/0011

  Cancer antigens · CPC title

• A61K2039/5156

  expressing foreign proteins · CPC title

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• C07K2319/42

  containing a HA(hemagglutinin)-tag · CPC title

• C12N15/8216

  Methods for controlling, regulating or enhancing expression of transgenes in plant cells · CPC title